<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182516</url>
  </required_header>
  <id_info>
    <org_study_id>PARPA-293-001</org_study_id>
    <secondary_id>2018-003918-40</secondary_id>
    <nct_id>NCT04182516</nct_id>
  </id_info>
  <brief_title>Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nerviano Medical Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nerviano Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I, first-in-human, open-label, multicenter, dose-escalation study with the aim of&#xD;
      exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP&#xD;
      inhibitor) as single agent in adult patients with selected advanced/metastatic,&#xD;
      relapsed/refractory solid tumors who have exhausted standard treatment options or for whom&#xD;
      standard therapy is considered unsuitable.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase 1 Dose escalation part followed by a Dose Expansion part.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with first-cycle dose limiting toxicity</measure>
    <time_frame>Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>From the Informed Consent signature to 28 days after the last dose of study treatment administration.</time_frame>
    <description>Safety will be assessed by AEs, which includes abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induces clinical signs or symptoms, needs active intervention, interruption or discontinuation of the study drug or is medically significant. A treatment-emergent AE is defined as abnormal AE observed after starting administration of the study drug up to 28 days after last dose of study medication intake. AEs will be coded with Medical Dictionary for Regulatory Activities and graded according to The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of NMS-03305293 after single and multiple doses of drug</measure>
    <time_frame>At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and Cycle 2 (Days 1, 8,15, 21) at different timepoints.</time_frame>
    <description>Plasma samples will be collected and used for pharmacokinetics assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to observed Cmax (Tmax) of NMS-033052293 after single and multiple doses of drug</measure>
    <time_frame>At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and Cycle 2 (Days 1, 8,15, 21) at different timepoints..</time_frame>
    <description>Plasma samples will be collected and used for pharmacokinetics assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve to the last of measurable concentration (AUClast) of NMS-033052293 after single and repeated dose of drug.</measure>
    <time_frame>At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and Cycle 2 (Days 1, 8,15, 21) at different timepoints.</time_frame>
    <description>Plasma samples will be collected and used for pharmacokinetics assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) of NMS-033052293 after single and multiple doses of drug.</measure>
    <time_frame>At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and Cycle 2 (Days 1, 8,15, 21) at different timepoints.</time_frame>
    <description>Plasma samples will be collected and used for pharmacokinetics assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration vs. time curve to infinity (AUCinf) of NMS-033052293 after multiple doses of drug.</measure>
    <time_frame>At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and Cycle 2 (Days 1, 8,15, 21) at different timepoints.</time_frame>
    <description>Plasma samples will be collected and used for pharmacokinetics assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) of NMS-033052293 after multiple doses of drug.</measure>
    <time_frame>At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and Cycle 2 (Days 1, 8,15, 21) at different timepoints.</time_frame>
    <description>Plasma samples will be collected and used for pharmacokinetics assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral plasma clearance (CL/F) of NMS-033052293 after multiple doses of drug.</measure>
    <time_frame>At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and Cycle 2 (Days 1, 8,15, 21) at different timepoints.</time_frame>
    <description>Plasma samples will be collected and used for pharmacokinetics assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vd/F) of NMS-033052293 after multiple doses of drug.</measure>
    <time_frame>At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and Cycle 2 (Days 1, 8,15, 21) at different timepoints.</time_frame>
    <description>Plasma samples will be collected and used for pharmacokinetics assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of NMS-033052293 after multiple doses of drug.</measure>
    <time_frame>At baseline, at Cycle 1 (each cycle is 28 days) Day 1 and Day 21.</time_frame>
    <description>Samples of urine will be used for pharmacokinetics assessments. In the dose escalation only: samples collected in all patients enrolled after the first DLT occurrence or starting the 4th dose level, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response (OR)</measure>
    <time_frame>At baseline, every even cycle (Day 28), at the end of treatment and at follow-up, every 8 weeks, till disease progression, an average 18 months.</time_frame>
    <description>Objective tumor response (OR) measured using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. For prostate cancer patients response will be evaluated by RECIST version 1.1/PCWG3 for patients with measurable disease and by Prostatic Specific Antigen (PSA) for all patients through PCWG3 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of first dose of study drug up to the date of first documentation of disease progression or death due to any cause, whichever comes first, an average of 2 years.</time_frame>
    <description>Progression Free Survival (PFS) will be calculated from the date of treatment initiation to the date of first documentation of disease progression according to RECIST 1.1 or RECIST 1.1/PCWG3 for patient with CRPC, or death due to any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression (TTP)</measure>
    <time_frame>From date of first dose of study drug up to the date of first documentation of disease progression or death due to progression, an average of 2 years.</time_frame>
    <description>Time to Progression (TTP) will be evaluated from the date of treatment initiation to the date of first documentation of disease progression according to RECIST 1.1 criteria or RECIST 1.1/PCWG3 for patient with CRPC, or death due to progression, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression (for prostate cancer only)</measure>
    <time_frame>From date of first dose of study drug up to the date of first documentation of PSA progression, an average of 1 year.</time_frame>
    <description>Time to PSA Progression will be calculated from the date of treatment initiation to the date of first documentation of PSA progression according to PCWG3 criteria.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced/Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with histologically confirmed diagnosis of locally advanced/metastatic HER2 negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC) or pancreatic cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Part - Epithelial Ovarian Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with gBRCA mutation and epithelial ovarian cancer previously treated with a PARP inhibitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Part - Pretreated HER 2 Neg. Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with gBRCA mutation and HER2 negative breast cancer previously treated with a PARP inhibitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Part - No Pretreated HER 2 Neg. Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with gBRCA mutation and HER2 negative breast cancer who have not received prior therapy with a PARP inhibitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Part - CRPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with gBRCA mutation and castration-resistant prostate cancer (CRPC) who have not received prior therapy with a PARP inhibitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Part - Pancreatic Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with gBRCA mutation and pancreatic cancer who have not received prior therapy with a PARP inhibitor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NMS-03305293</intervention_name>
    <description>All patients will receive NMS-03305293 administered orally once daily on Days 1-21 in repeated 4-week cycles.</description>
    <arm_group_label>Dose Escalation Part</arm_group_label>
    <arm_group_label>Dose Expansion Part - CRPC</arm_group_label>
    <arm_group_label>Dose Expansion Part - Epithelial Ovarian Cancer</arm_group_label>
    <arm_group_label>Dose Expansion Part - No Pretreated HER 2 Neg. Breast Cancer</arm_group_label>
    <arm_group_label>Dose Expansion Part - Pancreatic Cancer</arm_group_label>
    <arm_group_label>Dose Expansion Part - Pretreated HER 2 Neg. Breast Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria for Dose Escalation and Dose Expansion Part:&#xD;
&#xD;
          1. Patients with histologically confirmed diagnosis of locally advanced/metastatic HER2&#xD;
             negative breast cancer, epithelial ovarian cancer, castration-resistant prostate&#xD;
             cancer (CRPC) or pancreatic cancer. BRCA1 and BRCA2 mutation status is not required&#xD;
             for enrollment in the Dose Escalation part, but enrichment with deleterious/pathogenic&#xD;
             BRCA carriers will be attempted.&#xD;
&#xD;
          2. Patients must have progressive disease defined by RECIST 1.1 following standard&#xD;
             therapy or be unsuitable for standard therapy. For CRPC patients, disease progression&#xD;
             at study entry is defined as one or more of the following three criteria (according to&#xD;
             PCWG2):&#xD;
&#xD;
               -  PSA progression defined by a minimum of three rising PSA levels with an interval&#xD;
                  of ≥ 1 week between each determination. The PSA value at the Screening visit&#xD;
                  should be ≥ 2.0 ng/ml (µg/L). If the third PSA value is less than second PSA, a&#xD;
                  fourth PSA must be repeated and if the value is higher than second it must be&#xD;
                  considered as progressive disease;&#xD;
&#xD;
               -  Soft tissue/visceral disease progression defined by RECIST 1.1;&#xD;
&#xD;
               -  Bone disease progression defined by two or more new lesions on bone scan.&#xD;
&#xD;
          3. Male or female patients with age ≥ 18 years.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.&#xD;
&#xD;
          5. Life expectancy of at least 3 months.&#xD;
&#xD;
          6. Signed and dated IEC or IRB-approved Informed Consent.&#xD;
&#xD;
          7. At least 4 weeks must have elapsed or, in absence of toxicity, 5 half-lives, since&#xD;
             completion of prior cancer therapy (at least 6 weeks for nitrosureas, mitomycin C and&#xD;
             liposomal doxorubicin) before Cycle 1 Day 1.&#xD;
&#xD;
          8. Prior platinum therapy is allowed provided that criteria for platinum refractory&#xD;
             disease are not met (see exclusion criterion n.3).&#xD;
&#xD;
          9. Prior treatment with PARP inhibitors is allowed in the Dose Escalation Part and&#xD;
             required in two Cohorts of the Dose Expansion Part (HER2 neg breast cancer and&#xD;
             epithelial ovarian cancer with prior therapy with a PARP inhibitor). It is not allowed&#xD;
             in the other cohorts of patients enrolled in the Dose Expansion.&#xD;
&#xD;
         10. Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer&#xD;
             therapy to NCI CTC (Version 5.0) Grade ≤ 1 or to the baseline laboratory values as&#xD;
             defined in Inclusion Criterion Number 11.&#xD;
&#xD;
         11. Adequate hematological profile, renal and hepatic functions.&#xD;
&#xD;
         12. All patients must agree before enrollment to undergo germline BRCA1 and BRCA2 testing&#xD;
             on blood. The test will be performed in a centralized laboratory selected by the&#xD;
             sponsor. Availability of an ad hoc blood sample is mandatory for central germline BRCA&#xD;
             analysis both in dose escalation and in dose expansion.&#xD;
&#xD;
         13. Patients must use effective contraception or abstinence. Female patients of&#xD;
             childbearing potential must agree to use effective contraception or abstinence during&#xD;
             the period of therapy and in the following 90 days after discontinuation of study&#xD;
             treatment. Male patients must be surgically sterile or must agree to use effective&#xD;
             contraception or abstinence during the period of therapy and in the following 90 days&#xD;
             after discontinuation of study treatment.&#xD;
&#xD;
         14. Capability to swallow capsules intact (without chewing, crushing, or opening).&#xD;
&#xD;
         15. Willingness and ability to comply with scheduled visits, treatment plan, laboratory&#xD;
             tests and other study indications or procedures.&#xD;
&#xD;
             Inclusion Criteria specific for Dose Expansion Part:&#xD;
&#xD;
         16. Patients must have deleterious/pathogenic germline BRCA1 or BRCA2 mutation confirmed&#xD;
             by the centralized laboratory selected by the Sponsor.&#xD;
&#xD;
         17. Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1&#xD;
             (RECIST) except for CRPC patient who can have non-measurable disease.&#xD;
&#xD;
         18. Patients must have received the following previous treatment:&#xD;
&#xD;
               -  HER2 negative breast cancer: no more than 3 prior chemotherapy regimens for&#xD;
                  locally advanced and/or metastatic disease (no limit on prior hormonal therapies&#xD;
                  or targeted anticancer therapies). At least 1 line of taxane or anthracycline&#xD;
                  based chemotherapy, if not contraindicated, in adjuvant/neoadjuvant or metastatic&#xD;
                  setting. If HR (Hormone Receptor) positive, at least 1 line of prior endocrine&#xD;
                  therapy.&#xD;
&#xD;
               -  Epithelial ovarian cancer: no more than 4 prior regimens for locally&#xD;
                  advanced/metastatic disease including at least 1 line of platinum based&#xD;
                  hemotherapy;&#xD;
&#xD;
               -  CRPC: no more than 4 prior regimens; must have received at least 1 prior NHA&#xD;
                  (e.g. abiraterone or enzalutamide) and a taxane. Ongoing androgen deprivation&#xD;
                  therapy with a GnRH analogue or orchiectomy (i.e., surgical or medical&#xD;
                  castration) is mandatory.&#xD;
&#xD;
               -  Pancreatic cancer: no more than 2 prior regimens. Patients may have received&#xD;
                  prior radiotherapies (not considered as a regimen).&#xD;
&#xD;
         19. Patients with controlled, asymptomatic CNS involvement, which has been stable for the&#xD;
             previous 4 weeks, are eligible. The use of seizure prophylaxis is allowed as long as&#xD;
             patients are taking non-enzyme-inducing anti-epileptic drugs (non-EIAEDs).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current enrollment in another therapeutic clinical trial.&#xD;
&#xD;
          2. Prior malignancy except for any of the following:&#xD;
&#xD;
               -  Prior BRCA-associated cancer as long as there is no current evidence of the prior&#xD;
                  cancer;&#xD;
&#xD;
               -  Carcinoma in situ or non-melanoma skin cancer;&#xD;
&#xD;
               -  A cancer diagnosed and definitively treated ≥ 5 years before enrolment with no&#xD;
                  subsequent evidence of recurrence;&#xD;
&#xD;
          3. Patients with prior platinum therapy exposure who had evidence of disease progression&#xD;
             during platinum treatment (refractory disease) and patients whose disease relapsed&#xD;
             within 6 months of the last dose of prior adjuvant or neo-adjuvant platinum therapy.&#xD;
&#xD;
          4. Patients who have received prior PARP inhibitors should be excluded in the Dose&#xD;
             Expansion part except for the cohorts of HER2 negative breast cancer patients with&#xD;
             prior PARP inhibitors and epithelial ovarian cancer patients with prior PARP&#xD;
             inhibitors.&#xD;
&#xD;
          5. Patients with known symptomatic brain metastases or leptomeningeal involvement.&#xD;
             Patients with asymptomatic brain metastases or leptomeningeal involvement are excluded&#xD;
             in the Dose Escalation Part only.&#xD;
&#xD;
          6. Treatment with systemic immune modulators such as corticosteroids at&#xD;
             prednisone-equivalent dose of &gt;10 mg/day, cyclosporine and tacrolimus or radiotherapy&#xD;
             within 28 days before Cycle 1 Day 1.&#xD;
&#xD;
          7. Prior high-dose chemotherapy with bone marrow or stem cell transplant.&#xD;
&#xD;
          8. Major surgery, other than diagnostic surgery, within 4 weeks prior to treatment.&#xD;
&#xD;
          9. Any of the following in the past 6 months: myocardial infarction, unstable angina,&#xD;
             coronary/peripheral artery bypass graft, symptomatic congestive heart failure,&#xD;
             cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein&#xD;
             thrombosis.&#xD;
&#xD;
         10. Pregnancy or breast-feeding women.&#xD;
&#xD;
         11. Known active infections (bacterial, fungal, viral including HIV positivity).&#xD;
&#xD;
         12. Active gastrointestinal disease (e.g., documented gastrointestinal ulcer, Crohn's&#xD;
             disease, ulcerative colitis, or short gut syndrome) or other syndromes that would&#xD;
             impact on drug absorption.&#xD;
&#xD;
         13. Patients with QTc interval ≥ 480 milliseconds or with risk factors for torsade de&#xD;
             pointes (e.g., heart failure, uncontrolled hypokalemia, family history of long QT&#xD;
             syndrome) or receiving treatment with concomitant medications known to prolong the&#xD;
             QT/QTc interval that cannot be replaced with another treatment.&#xD;
&#xD;
         14. Patients receiving treatment with concomitant medications known to be CYP2D6 and&#xD;
             CYP2C19 sensitive substrates that cannot be replaced with another treatment.&#xD;
&#xD;
         15. Other severe acute or chronic medical or psychiatric condition (including history of&#xD;
             seizure disorder) or laboratory abnormality that may increase the risk associated with&#xD;
             study participation or study drug administration or may interfere with the&#xD;
             interpretation of study results and, in the judgment of the Investigator, would make&#xD;
             the patient inappropriate for entry into this study or could compromise protocol&#xD;
             objectives in the opinion of the Investigator and/or the Sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PierFranco Conte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Oncologico Veneto IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank X. Gan, PharmD</last_name>
    <phone>+39 .334.6513171</phone>
    <email>frank.gan@nervianoms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela M. Ghioni, PhD</last_name>
    <phone>+39033158</phone>
    <phone_ext>1676</phone_ext>
    <email>pamela.ghioni@nervianoms.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Ricerche Cliniche di Verona Srl</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2 negative breast cancer</keyword>
  <keyword>Epithelial ovarian cancer</keyword>
  <keyword>Castration-resistant prostate cancer (CRPC)</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>BRCA1 Gene Mutation</keyword>
  <keyword>BRCA2 Gene Mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

